SCYNEXIS Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

SCYNEXIS heeft een totaal eigen vermogen van $58.5M en een totale schuld van $13.2M, wat de schuld-eigenvermogensverhouding op 22.6% brengt. De totale activa en totale passiva bedragen respectievelijk $99.0M en $40.5M.

Belangrijke informatie

22.6%

Verhouding schuld/eigen vermogen

US$13.23m

Schuld

Rente dekkingsratio	n/a
Contant	US$68.83m
Aandelen	US$58.53m
Totaal verplichtingen	US$40.51m
Totaal activa	US$99.04m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $80.5M ) 135A } overtreffen de korte termijn passiva ( $25.7M ).

Langlopende schulden: De kortetermijnactiva 135A ( $80.5M ) overtreffen de langetermijnschulden ( $14.8M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 135A heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 135A is de afgelopen 5 jaar gedaald van 130.8% naar 22.6%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 135A heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of 135A voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

SCYNEXIS Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023)

New major risk - Revenue and earnings growth

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

Full year 2023 earnings released: EPS: US$1.40 (vs US$1.47 loss in FY 2022)

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.62 loss in 3Q 2022)

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.17 loss in 1Q 2022)

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Insufficient new directors

Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.023 loss in 3Q 2021)

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.064 profit in 2Q 2021)

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

No longer forecast to breakeven

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections

Insufficient new directors

Forecast to breakeven in 2024

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Scynexis, Inc. Announces Peer-Reviewed Publication of Results

Scynexis, Inc. Announces U.S. Availability of BREXAFEMME®

Scynexis, Inc. Announces Hansoh Pharma’S Application to National Medical Products Administration (Nmpa) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (Vvc)

SCYNEXIS, Inc. Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and in Vitro Activity Against Candida Species At the 31st ECCMID

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

Forecast breakeven pushed back to 2024

SCYNEXIS, Inc. Provides an Update on Recent Clinical and Corporate Developments

SCYNEXIS, Inc. announced that it expects to receive funding from Hercules Capital, Inc.

Scynexis Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (Furi and Cares)

SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of Brexafemme (Ibrexafungerp) for Vaginal Yeast Infections

SCYNEXIS, Inc. Enter into an Exclusive License and Collaboration Agreement with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited

New 90-day high: €7.00

New 90-day high: €6.50

CEO, President & Director recently bought €205k worth of stock

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $84.99474 million.

New 90-day high: €6.45

SCYNEXIS, Inc. Announces Significant Progress on the Ibrexafungerp IV Formulation and Provided an Update on Its Ongoing Phase 3 Studies in the Hospital Setting

New 90-day high: €5.75

Revenue in line with expectations

SCYNEXIS, Inc. Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection

New 90-day low: €3.88

New 90-day low - €5.14

SCYNEXIS, Inc.(NasdaqGM:SCYX) dropped from Russell Microcap Index

SCYNEXIS, Inc.(NasdaqGM:SCYX) dropped from Russell Microcap Value Index

Analyse van de financiële positie